miR-539-5p通过准KDM6A来调节刺激性肠综合征的病理过程
Yiqun Li1, Zhiyu Wang1, Shuangshuang Zhang1
1Institute of Digestive Diseases, Xuzhou Medical University, Jiangsu, China.
概括
微RNA-539-5p在刺激性肠综合征与腹 (IBS-D) 中是下调的. 恢复其水平通过准KDM6A来缓解IBS-D症状,提供潜在的治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 微RNA研究 微RNA研究
背景情况:
- 刺激性肠综合征 (IBS) 由于其慢性和反复性质,对健康构成重大负担.
- 了解IBS的分子机制对于开发有效的治疗方法至关重要.
研究的目的:
- 研究微RNA-539-5p (miR-539-5p) 在IBS中的作用和调节机制.
- 探索miR-539-5p作为IBS的潜在治疗点.
主要方法:
- 已建立的IBS与腹 (IBS-D) 的老鼠模型和使用脂多糖 (LPS) 的体外细胞模型.
- 使用实时定量聚合酶连锁反应的量化miR-539-5p表达.
- 使用CCK-8,流细胞计和ELISA评估细胞活力,细胞亡和炎症.
- 利用生物信息学和双露西法酶记者测试来确定KDM6A作为miR-539-5p的目标基因.
主要成果:
- 在IBS-D大鼠和LPS治疗细胞中,miR-539-5p的表达显著下调.
- 过度表达miR-539-5p改善了老鼠的IBS-D症状,并保护了肠道细胞免受LPS诱导的损伤.
- miR-539-5p抑制了亡,促进了增殖,降低了细胞透性,并抑制了炎症.
- 在IBS-D模型中,KDM6A被上调调节,其过度表达抵消了miR-539-5p的保护作用.
结论:
- miR-539-5p在IBS-D的病理过程中起着至关重要的作用.
- miR-539-5p/KDM6A轴是IBS-D的一个关键调节途径.
- miR-539-5p代表了IBS-D的有希望的治疗标.
相关概念视频
01:17Irritable Bowel Syndrome I: Introduction
924
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
924
01:17Drugs for Treatment of Diarrhea-Predominant IBS
635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
01:17Chronic Bowel Disorders: Introduction
747
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
747
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
732
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
732
01:21Drugs for Treatment of Constipation-Predominant IBS
726
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
726
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
903
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
903